The U.S. government on Monday started a review process for national Medicare coverage of Biogen Inc's Alzheimer's drug, Aduhelm, that was recently approved by the country's health regulator.
The Centers for Medicare & Medicaid Services expects to give a proposed decision within 6 months and a final decision within 9 months. (https://go.cms.gov/3hzMa6H)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.